Healing & Recovery peptides

20 peptides tagged healing & recovery. Each page carries the dosing reference, mechanism, evidence grade and references.

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

  • ARA-290

    Synthetic 11-amino-acid peptide derived from the helix-B region of erythropoietin that activates the innate repair receptor without EPO's blood-cell effects.

    Evidence: Clinical

  • B7-33

    Single-chain 27-residue mimetic of the human relaxin-2 B chain that biases RXFP1 signaling toward pERK; reduced cardiac and lung fibrosis in rodent models.

    Evidence: Preclinical

  • BPC-157

    Synthetic pentadecapeptide derived from a protective protein found in human gastric juice; accelerates tendon, muscle and gut healing in rodent models.

    Evidence: Preclinical

  • BPC-157 + TB-500 + GHK-Cu (Glow Blend)

    Vial blend of BPC-157, TB-500 (Ac-LKKTETQ) and GHK-Cu, sold mostly as 70 mg (10/10/50 mg); each component has animal or cell data, and no study has tested the three together.

    Evidence: Preclinical

  • BPC-157 + TB-500 + KPV + GHK-Cu (KLOW Blend)

    Vial blend of BPC-157, TB-500 (Ac-LKKTETQ), KPV and GHK-Cu, sold as 80 mg (10/10/10/50 mg); each component has animal or cell data, and no study has tested the four together.

    Evidence: Preclinical

  • BPC-157 + TB-500 Blend

    Vial blend of BPC-157 and TB-500 (Ac-LKKTETQ), two peptides with rodent tissue-repair data; the one rat study of the pair found no added benefit over either alone.

    Evidence: Preclinical

  • BPC-157 Capsule

    Oral capsule form of the gastric pentadecapeptide BPC-157, studied mainly in rodent models for gastrointestinal mucosal repair and systemic tissue healing.

    Evidence: Preclinical

  • GHK Basic

    Copper-free form of the human tripeptide GHK (Gly-His-Lys), studied for collagen synthesis and wound repair, though nearly all published data use the copper complex.

    Evidence: Preclinical

  • GHK-Cu

    Copper complex of the tripeptide Gly-His-Lys, isolated from human plasma in 1973; raises collagen synthesis in cell and rat studies, with mixed results in small topical human trials.

    Evidence: Preclinical

  • IGF-1 DES

    Truncated IGF-1 missing the N-terminal Gly-Pro-Glu; about 10x as potent as IGF-1 on cultured cells, because losing Glu3 removes most IGF-binding-protein binding. Occurs naturally in colostrum, brain and uterus.

    Evidence: Preclinical

  • IGF-1 LR3

    IGF-1 analog with Glu3 replaced by Arg plus a 13-residue N-terminal extension, which binds IGF-binding proteins poorly; in animals it is 2 to 3x as potent as IGF-1 at lowering glucose and is cleared faster, not slower.

    Evidence: Preclinical

  • KPV

    C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH; shown in animal and cell models to suppress NF-kB inflammatory signaling in gut and skin without pigmentation effects.

    Evidence: Preclinical

  • Larazotide

    Synthetic octapeptide (AT-1001) that blocks zonulin-mediated opening of intestinal tight junctions; tested in human celiac disease trials as an adjunct to a gluten-free diet.

    Evidence: Clinical

  • LL-37

    The 37-residue human cathelicidin peptide, an innate-immune effector with broad antimicrobial activity; studied topically in human chronic wound-healing trials and as an immune modulator.

    Evidence: Clinical

  • MGF (IGF-1 Ec)

    The IGF-1Ec splice variant and its synthetic 24-residue E-domain peptide; mRNA rises in loaded human muscle, but the peptide's proliferative effect failed to replicate and no endogenous peptide has been isolated.

    Evidence: Preclinical

  • PEG-MGF

    PEGylated version of mechano growth factor (the IGF-1Ec splice variant), sold as a research chemical; no published pharmacology or human data exist for the PEGylated form.

    Evidence: Anecdotal

  • PTD-DBM

    Cell-permeable peptide that blocks the CXXC5-Dishevelled interaction to de-repress Wnt/beta-catenin signaling; studied topically in mice for hair regrowth and wound healing.

    Evidence: Preclinical

  • TB-500

    Acetylated heptapeptide Ac-LKKTETQ, the actin-binding region (residues 17 to 23) of thymosin beta-4 and not the full 43-residue protein; it promoted angiogenesis and wound repair in animal and cell models.

    Evidence: Preclinical

  • TB-500 Fragment (17-23)

    Ac-LKKTETQ, the actin-binding heptapeptide of Thymosin Beta-4, studied in animal models for cell migration, angiogenesis, wound healing and tissue repair.

    Evidence: Preclinical

  • Thymosin Beta-4 Fragment Capsule

    Oral capsule formulation of a Thymosin Beta-4 active fragment sold for recovery; short peptides are poorly absorbed from the gut and no human data support this route.

    Evidence: Anecdotal

Other categories